

## STEM CELL DISORDERS

Myelodysplatic Syndrome (MRS)


# Myelodysplastic Syndrome (MDS). The importance of evaluating multiple cell lineages and maturation stages.


In patients with MDS the role for flow cytometric immunophenotyping is not fully established, but recently immunophenotyping was included as one of the co-criteria for the

diagnosis of MDS. (12) Several studies indeed have shown that immunophenotypic abnormalities can be detected in the vast majority of MDS patients, including abnormalities in lineages (or cases) with normal cytomorphological appearance. (13,14) However, since many immunophenotypic abnormalities are not specific for MDS, flow cytometric scoring systems are needed, but so far, they have not been standardized. (15, 16-22)


International harmonization of flow cytometry MDS diagnostics is currently in progress. (23, 24)

Example of data analysis in a case with diagnosis of low grade MDS, where no overt increased blasts by morphology.






### CD34+ SUBSETS



### BASOPHILS / DENDRITIC / MAST CELLS



#### **ERYTHROID MATURATION** HH-20-262 LS 03-10-20\_8- New RBC\_008.fcs compensatedViable sin HH-20-262 LS 03-10-20\_8- New RBC\_008.fcs compensatedERY % of 2 bright CD105+ Gate 19503 gated cells None 100.00 **Y** 127933 3 interm CD105+ 1 ERYTHROID 34+ 0.00 **PSC-A** 127933 2 bright CD105+ 10.51 4 CD105 negative 3 interm CD105+ 15.82 4 CD105 negative 69.37 60828 60828 -6277 10<sup>5</sup> 10<sup>2</sup> -10<sup>1</sup> 10<sup>3</sup> CD45 -10<sup>2</sup>0 10<sup>3</sup> CD105 HH-20-262 LS 03-10-20\_8- New RBC 008.fcs compensat CD36 CD102 CD36 10<sup>3</sup> 10<sup>3</sup> 10<sup>2</sup> 10<sup>2</sup> 10<sup>2</sup> -10<sup>1</sup> -10 -10<sup>1</sup> -10<sup>2</sup> 10<sup>3</sup> 10<sup>4</sup> CD105 -10<sup>2</sup>0 10<sup>5</sup> -10<sup>2</sup> 10<sup>0</sup> 10<sup>2</sup> 104 10<sup>3</sup> CD117 GlyA